Landmark Ideas Series: Dr. Mollyann Brodie

Speaker: Mollyann Brodie, PhD, at the Kaiser Family Foundation

Date: January 29, 2024 at 4:00PM - 5:30PM

Talk details will be forthcoming.

Mollyann Brodie is Executive Vice President and Chief Operating Officer at KFF and Executive Director of KFF’s Public Opinion and Survey Research Program. As COO, Dr. Brodie oversees KFF’s budgeting, human resources, facilities management, and the executive operations of the President’s Office and Board of Trustees. As ED of Public Opinion and Survey Research, she oversees KFF’s polling work including the Covid-19 Vaccine Monitor, the monthly Health Tracking Poll and ongoing survey partnerships with news media organizations. A distinguished public opinion scholar, Dr. Brodie’s research efforts focus on understanding the U.S. public’s views and knowledge on health care policy issues, and the role of opinion in health policy debates. Her research has been published in the Journal of the American Medical Association; New England Journal of Medicine; Journal of Health Politics, Policy, and Law; and Health Affairs. She is co-editor of the book American Public Opinion and Health Care (CQ Press, 2011). Dr. Brodie is a Past President of the American Association for Public Opinion Research (AAPOR) and the 2018 recipient of the Roper Center’s Warren J. Mitofsky Award for Excellence in Public Opinion Research. She received a M.S. in Health Policy and Management and a Ph.D. in Health Policy from Harvard University.


Publications

Hopper RK, Abman SH, Elia EG, Avitabile CM, Yung D, Mullen MP, Austin ED, Bates A, Handler SS, Feinstein JA, Ivy DD, Kinsella JP, Mandl KD, Raj JU, Sleeper LA, . Pulmonary Hypertension in Children with Down Syndrome: Results from the Pediatric Pulmonary Hypertension Network Registry. The Journal of pediatrics 2022.

Wang X, Zhang HG, Xiong X, Hong C, Weber GM, Brat GA, Bonzel CL, Luo Y, Duan R, Palmer NP, Hutch MR, Gutiérrez-Sacristán A, Bellazzi R, Chiovato L, Cho K, Dagliati A, Estiri H, García-Barrio N, Griffier R, Hanauer DA, Ho YL, Holmes JH, Keller MS, Klann MEng JG, L'Yi S, Lozano-Zahonero S, Maidlow SE, Makoudjou A, Malovini A, Moal B, Moore JH, Morris M, Mowery DL, Murphy SN, Neuraz A, Yuan Ngiam K, Omenn GS, Patel LP, Pedrera-Jiménez M, Prunotto A, Jebathilagam Samayamuthu M, Sanz Vidorreta FJ, Schriver ER, Schubert P, Serrano-Balazote P, South AM, Tan ALM, Tan BWL, Tibollo V, Tippmann P, Visweswaran S, Xia Z, Yuan W, Zöller D, Kohane IS, Avillach P, Guo Z, Cai T, . SurvMaximin: Robust federated approach to transporting survival risk prediction models. Journal of biomedical informatics 2022.

Torous J, Stern AD, Bourgeois FT. Regulatory considerations to keep pace with innovation in digital health products. NPJ digital medicine 2022.

Levy S, Wisk LE, Minegishi M, Ertman B, Lunstead J, Brogna M, Weitzman ER. Association of Screening and Brief Intervention With Substance Use in Massachusetts Middle and High Schools. JAMA network open 2022.

Nielsen M, Presti M, Sztupinszki Z, Jensen AWP, Draghi A, Chamberlain CA, Schina A, Yde CW, Wojcik J, Szallasi Z, Crowther MD, Svane IM, Donia M. Co-existing alterations of MHC class I antigen presentation and IFNγ signaling mediate acquired resistance of melanoma to post-PD-1 immunotherapy. Cancer immunology research 2022.